The Motley Fool··Prosper Junior BakinyTwo Biotech Stocks Poised to Outpace Summit Therapeutics Amid FDA Uncertainty
Summit Therapeutics faces FDA decision on ivonescimab by November 2026 amid efficacy concerns, while Axsome and Madrigal positioned for outperformance.
AXSMMDGLSMMTregulatory riskFDA approval